IP Library Granted Patent US 11,467,159
Granted Patent B2
US 11,467,159 · App. 15/623,309 · Granted Oct 11, 2022

Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells

Inventors: Jamey P. Weichert (Madison, WI); Chorom Pak (Madison, WI); Anatoly Pinchuk (Madison, WI); Kevin Kozak (Madison, WI); Marc Longino (Madison, WI)
Assignee: CELLECTAR BIOSCIENCES, INC.
G01N33/574G01N15/14G01N33/54326G01N33/57492G01N33/582G01N21/6428G01N2015/0065G01N2015/1006G01N2021/6439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,467,159
App. No.
15/623,309
Granted
Oct 11, 2022
Kind
B2
Abstract

The present invention is directed to a method of identifying, isolating, and enabling downstream analysis of circulating tumor cells comprising contacting a blood or blood serum sample of a subject with a composition comprising a phospholipid ether analog bound to a luminescent molecule or a magnetic bead and subjecting the blood or blood serum sample of the subject to fluorescent microscopy, flow cytometry or magnetic isolation.

Claims (18)

1. A method of isolating tumor cells comprising the steps of:

(i) contacting a blood or blood serum sample from a subject having one or more circulating tumor cells (CTCs) with a compound of formula (I),

wherein:

n is an integer from 16 to 30;

Y is selected from the group consisting of —H, —OH, —OR, —C(O)OH, and —OC(O)R, wherein R is an alkyl; and

X is a luminescent molecule;

(ii) subjecting the blood or blood serum sample to flow cytometry; and

(iii) isolating the one or more CTCs following (ii),

wherein the one or more CTCs are selected from the group consisting of a breast cancer cell, a lung cancer cell, a thyroid cancer cell, a cervical cancer cell, a squamous cell, a carcinoma cell, a prostate cancer cell, a pancreas cancer, a colorectal cancer cell, and a cancer stem cell.

2. The method of claim 1 , wherein the luminescent molecule is a fluorophore.

3. The method of claim 2 wherein the fluorophore is selected from the group consisting of

wherein each R of the fluorophore is independently H, CH 3 , C 2 H 5 , or C 3 H 7 .

4. The method of claim 3 wherein the compound is a compound of formula (II) and the fluorophore is selected from the group consisting of

5. The method of claim 1 , wherein the flow cytometry comprises fluorescence activated cell sorting.

6. The method of claim 1 , further comprising utilizing the one or more isolated CTCs in a technology selected from the group consisting of protein isolation, RNA isolation, DNA isolation, gene translocation analysis, gene amplification analysis, and fluorescent in-situ hybridization.

7. The method of claim 1 , wherein the one or more circulating tumor cells are prostate cancer cells.

8. The method of claim 7 , wherein the compound is a compound of formula (V),

or a compound of formula (VI),

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2018
From: WEICHERT, JAMEY
To: CELLECTAR BIOSCIENCES, INC.
Reel/Frame 047747/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2018
From: LONGINO, MARC
To: CELLECTAR BIOSCIENCES, INC.
Reel/Frame 046646/0131 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2018
From: KOZAK, KEVIN; PINCHUK, ANATOLY; PAK, CHOROM
To: CELLECTAR BIOSCIENCES, INC.
Reel/Frame 046573/0297 →
Continuity (2)
Provisional Application 62349713 · Jun 14, 2016
Related Publication 20170356914A1 · Dec 14, 2017